Clinical Trials Logo

Alzheimer Disease clinical trials

View clinical trials related to Alzheimer Disease.

Filter by:
  • Terminated  
  • « Prev · Page 24

NCT ID: NCT00287742 Terminated - Dementia Clinical Trials

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease

Start date: March 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo for the treatment of patients with hallucinations and delusions associated with Alzheimer's disease.

NCT ID: NCT00165750 Terminated - Alzheimer's Disease Clinical Trials

Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients

Start date: March 2005
Phase: Phase 4
Study type: Interventional

This study investigate the relationship between regional brain volume measured by MRI and donepezil treatment response in patients with Alzheimer's Disease.

NCT ID: NCT00160147 Terminated - Clinical trials for Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

Start date: December 2005
Phase: Phase 3
Study type: Interventional

This is a 10-week study with bifeprunox and placebo in elderly subjects with psychosis and behavioral disturbances associated with dementia of the alzheimer's type.

NCT ID: NCT00105105 Terminated - Alzheimer's Disease Clinical Trials

Mifepristone as Adjunctive Therapy in Alzheimer's Disease

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effects of C-1073 (Mifepristone) on cognition in patients with Alzheimer's disease (AD) who are also taking an acetylcholinesterase inhibitor (Aricept, Exelon or Reminyl).

NCT ID: NCT00087724 Terminated - Alzheimer's Disease Clinical Trials

A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease

Start date: July 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of five fixed dosage levels of FK962 or placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease. Patient visits are every six weeks with limited efficacy measurements at week 6 and 18.

NCT ID: NCT00069849 Terminated - Alzheimer's Disease Clinical Trials

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Start date: July 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the safety and efficacy of 2 mg, 4 mg, and 20 mg of ABT-089 BID to placebo in adults with Alzheimer's disease.

NCT ID: NCT00021723 Terminated - Alzheimer's Disease Clinical Trials

Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

Start date: September 2001
Phase: Phase 2
Study type: Interventional

A multi-center, double-blind, placebo-controlled out-patient, safety, tolerability, and pilot efficacy study of intramuscular AN-1792 in patients with mild to moderate Alzheimer's disease.

NCT ID: NCT00006187 Terminated - Alzheimer Disease Clinical Trials

The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease

Start date: n/a
Phase: Phase 3
Study type: Interventional

This is a 15-month study with two phases. During the first 12-month phase of this study, patients will be randomly assigned to receive either active study drug or placebo (approximately half of all patients will be on active study drug, the other half on placebo). The second phase is a 3-month randomized withdrawal period. For this phase approximately 10% of the patients will remain on the active drug.

NCT ID: NCT00001178 Terminated - Dementia Clinical Trials

Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders

Start date: January 19, 1981
Phase:
Study type: Observational

The Cognitive Neuroscience Section of the National Institute of Neurological Disorders and Stroke proposes to continue its cross-sectional and longitudinal studies of cerebral metabolism in frontal lobe dementias and atypical basal ganglia disorders. These studies include repeated assessments of neuropsychological and brain anatomical and metabolic function in subjects with these important and possibly related brain disorders.